Colorectal cancer includes cancers of the colon and rectum that arise from the lining of the large intestine, often evolving from precancerous polyps.
Researchers identify DPY30 as an epigenetic target to sensitize pancreatic tumors to immunotherapy. UC San Diego researchers redirect CMV immunity against pancreatic cancer in preclinical models. A Fred Hutch researcher receives ACS grant to study immunotherapy resistance in melanoma.
Elicio Therapeutics granted inducement stock options to new employees, with one grant of 1,600 options at $12.16 per share and another of 30,300 options at $8.59 per share. The clinical-stage biotech company is developing novel immunotherapies targeting mKRAS-positive cancers, with its ELI-002 program showing promising Phase 1 results including 16.3-month median recurrence-free survival.
GSK's antibody-drug conjugate risvutatug rezetecan has received Orphan Drug Designation in Japan for small-cell lung cancer, marking its sixth global regulatory designation. The decision was based on phase I trial data showing durable responses in extensive-stage SCLC patients. The drug is currently in phase III development for relapsed ES-SCLC.
The global oncology precision medicine market is projected to grow from $190.50 billion in 2026 to $366.53 billion by 2033 at a 9.8% CAGR, while the cancer biomarker testing market is expected to reach $96.53 billion by 2033 at a 12.6% CAGR.
ImmunityBio's stock jumped 41.9% following the European Commission's conditional marketing authorization for Anktiva combined with BCG to treat BCG-unresponsive non-muscle invasive bladder cancer across 33 European countries.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07519681 |
Effects of Berberine on the Human Gut Microbiome |
NOT_YET_RECRUITING | NA |
| NCT06586307 |
Estimating Lymphocyte Counts from DNA Methylation |
COMPLETED | |
| NCT04491955 |
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers |
COMPLETED | PHASE2 |
| NCT02046174 |
Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared to Best Supportive Care in Colorectal Cancer Patients |
COMPLETED | PHASE2 |
| NCT01828918 |
Biomarkers for the Early Diagnosis, Prediction, Prognosis for Colorectal Cancers |
UNKNOWN | PHASE1 |
